24 results on '"Gerth, William C."'
Search Results
2. The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy
3. Compliance and persistence with newer antihypertensive agents
4. Improvement in Health-Related Quality of Life with Rizatriptan 10mg Compared with Standard Migraine Therapy
5. The Multinational Impact of Migraine Symptoms on Healthcare Utilisation and Work Loss
6. Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis
7. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever
8. Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan
9. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions
10. Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?
11. Burden of hospitalization of patients with Candida and Aspergillus infections in Australia
12. Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease: The RENAAL study economic evaluation
13. The Cost-Effectiveness of Losartan versus Captopril in Patients with Symptomatic Heart Failure
14. Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union
15. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes
16. Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
17. Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
18. Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries.
19. Losartan/angiotensin II antagonists have greater persistence than other antihypertensive agents/classes
20. O-23: Angiotensin II antagonists demonstrate greater long-term persistence versus other antihypertensive medications.
21. Angiotensin II antagonists demonstrate greater long-term persistence versus other antihypertensive medications
22. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
23. Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial.
24. Antihypertensive persistence and drug class.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.